Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

23.89
+0.50502.16%
Post-market: 23.890.00000.00%16:10 EDT
Volume:2.04M
Turnover:48.89M
Market Cap:2.99B
PE:110.88
High:24.18
Open:23.63
Low:23.55
Close:23.38
52wk High:31.77
52wk Low:16.57
Shares:125.07M
Float Shares:111.18M
Volume Ratio:0.90
T/O Rate:1.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:13.54
PE(LYR):-188.28

Loading ...

Earning Preview: Arcutis Biotherapeutics Inc. this quarter’s revenue is expected to increase by 62.67%, and institutional views are bullish

Earnings Agent
·
Apr 30

Arcutis submits FDA sNDA for Zoryve cream use in infants with atopic dermatitis

Reuters
·
Apr 27

Arcutis Submits Supplemental New Drug Application to the FDA for Zoryve® (Roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

THOMSON REUTERS
·
Apr 27

A Look At Arcutis Biotherapeutics (ARQT) Valuation After New Pediatric Guidelines For ZORYVE

Simply Wall St.
·
Apr 25

Arcutis’ Zoryve® (Roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

THOMSON REUTERS
·
Apr 22

Arcutis Biotherapeutics announces annual shareholder meeting

Reuters
·
Apr 22

Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities

TIPRANKS
·
Apr 14

Why Arcutis Biotherapeutics (ARQT) Is Up 10.9% After Positive Infant Atopic Dermatitis Trial Data And What's Next

Simply Wall St.
·
Apr 07

Arcutis director Howard G. Welgus disposes of common shares worth $0.2 million

Reuters
·
Apr 04

Arcutis management to present at Needham Virtual Healthcare Conference fireside chat

Reuters
·
Apr 01

How New Infant Atopic Dermatitis Data And sNDA Plans At Arcutis (ARQT) Have Changed Its Investment Story

Simply Wall St.
·
Mar 30

Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream

TIPRANKS
·
Mar 29

Arcutis says Phase 2 trial shows Zoryve cream improves infant atopic dermatitis

Reuters
·
Mar 28

A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Mar 19

Arcutis Biotherapeutics to present clinical data on ZORYVE at AAD Meeting

TIPRANKS
·
Mar 18

Arcutis to present new ZORYVE trial data at American Academy of Dermatology annual meeting

Reuters
·
Mar 18